Description
Daratumumab, marketed under the brand name DARZALEX, It is an prescription medication that has been Approved by U.S. FDA: First Human Anti-CD38 Monoclonal Antibody Available for the Treatment of Multiple Myeloma.” Issued November 16, 2015.
What is DARZALEX (Daratumumab) ?
DARZALEX® is a prescription medicine used to treat multiple myeloma: In combination with the medicines lenalidomide and dexamethasone or bortezomib and dexamethasone, in people who have received at least one prior medicine to treat multiple myeloma.
Daratumumab (trade name Darzalex) is an anti-cancer drug. It binds to CD38, which multiple myeloma cells overexpress. In November 2015, the U.S. Food and Drug Administration (FDA) approved daratumumab for treatment of multiple myeloma in patients who had received at least three prior therapies. In May 2016 daratumumab was also conditionally approved by the European Medicines Agency for treatment of multiple myeloma.
Source Content From US FDA
How to order approved “DARZALEX (Daratumumab) for injection” Medicine?
DARZALEX (Daratumumab) injection is a prescription medicine, it can be accessed through the Named Patient Program (NPP) for treatment in the following city of India – Bengaluru, Delhi, Chennai, Hyderabad, Mumbai, Pune, Kolkata, Ahmedabad, Gurgaon. To inquire about the cost price of purchasing DARZALEX and arranging delivery to your location, please get in touch with Mr. Rakesh at +91 9910645395 or send an enquiry to info@cancermedicinesnetwork. We assure you of the quality of the product and guarantee delivery in accordance with your specific requirements.
